Neither the brand nor the generic drug lobby appear keen on FDA Commissioner Scott Gottlieb’s idea to publish the letters it sends to brand companies explaining that a potential generic competitor has adequate safety protections in place to be sold brand drug samples for the bioequivalence testing required as a prerequisite of generic approval. Generics worry the letters could lead to competition problems, while brands worry the letters without the proper context could soil their reputation. Gottlieb announced during a...